

REMARKS

Favorable reconsideration and allowance of this application are requested.

By way of the amendment instructions above, appropriate application headings have been inserted into the specification along with a Brief Description of originally filed Figs. 1 and 2. See in this regard, page 18, lines 10-11 and page 20, lines 26-27 for support of such descriptions.

The subject matter of allowable claim 10 has been incorporated into claim 1. As such, claim 10 has been cancelled. It will be observed in this regard, however, that reference to the second phosphine ligand has been characterized as a "make-up" ligand for purpose of clarity. The remaining dependent claims have been amended as needed so as to conform to the amended version of independent claim 1.

Claim 21 is new and clarifies that the second ligand may optionally be added to the process ligand prior to introduction of the process ligand to the process. Support for such new claim may be found in FIGS. 1 and 2 and the description thereof (e.g., see page 20, lines 14-20).

Since only allowable subject matter is now defined in the pending claims herein, the rejection advanced on the basis of 35 USC §103(a) has been rendered moot. Early receipt of the Official Allowance Notice is therefore solicited.

SIELCKEN et al
Serial No. 10/565,773
April 7, 2008

Fee Authorization

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Bryan H. Davidson/
Bryan H. Davidson
Reg. No. 30,251

BHD:dlb
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100